Cleo Diagnostics Ltd (ASX:COV)

Market Cap	43.19M -17.0%
Revenue (ttm)	1.72M +103.2%
Net Income	-5.94M
EPS	-0.04
Shares Out	137.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,552
Open	0.3150
Previous Close	0.3150
Day's Range	0.2920 - 0.3250
52-Week Range	0.2920 - 0.9000
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 24, 2026

About Cleo Diagnostics

Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: COV

Financial Performance

In fiscal year 2026, Cleo Diagnostics's revenue was 1.72 million, an increase of 103.17% compared to the previous year's 845,172. Losses were -5.94 million, 48.4% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 17, 2026

Data Sources Report a data error